- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05536986
Correlation Between Psychological Stress and Progression of Newly Oligodendroglioma Towards Secondary Glioma
Correlation Between Psychological Stress and Progression of Newly Oligodendroglioma Towards Secondary Glioma: A Longitudinal Study Based on Long-term Follow-up
It is a single-center, prospective, observational, non-randomized study of newly diagnosed oligodendroglioma patients conducted in a tertiary hospital. The investigators conduct an eight-year follow-up, including patients' psychological stress, immune biomarker changes, quality of life, and disease progression of patients towards secondary glioma after the first definite diagnosis. In the first year after diagnosis, patients are followed up four times at 1 month, 3 months, 6 months, and 12 months. After that, patients are followed up semiannually.
The study had two cohorts, a high-stress cohort and a low-stress cohort, which are grouped after initial recruitment. Both groups undergo total resection of tumors and received 3 months of standardized treatment with radiotherapy and chemotherapy. Neither participants nor doctors but the researcher can choose which group participants are in. No one knows if one study group is better or worse than the other.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Oligodendroglioma belongs to the class of gliomas that represent the most common class of primary malignant human brain tumors in adulthood. After tumor resection, patients still face the possibility of recurrence and even progression to glioblastoma. The immune microenvironment is most likely contributing to their development, but underlying pathomechanisms are only partly understood.
The high-level psychological stress can lead to a change in malignant tumors patients' neuroendocrine pathways and correlates with the prognosis outcome. In addition, psychological stress can lead to changes in the immune microenvironment, but if it leads to disease progression in oligodendroglioma towards secondary glioma has not been adequately demonstrated.
Grouping process: 60 patients are expected to be enrolled. After enrollment, participants will receive regular tumor in situ fluid (fluid within the surgical cavity, TISF) sampling for tumor mutation burden (TMB) analysis and regular MRI. Under the standard of care, participants will receive psychological stress assessment after being diagnosed. according to five psychological scales, and the patients were grouped according to the cut-off value of each scale, the psychological stress of the patients is measured by distress thermometer (DT), perceived stress scale (PSS), anxiety/depression (HADS), and fear of disease progression scale (PoP-Q-SF).
Primary study objectives:
- To evaluate the proportion of patients with tumor recurrence
- To evaluate the changes in immune markers of acute and chronic psychological stress in patients with oligodendroglioma after diagnosis.
- To analyze the classification of recurrent glioma.
Secondary study objectives:
- To evaluate the progression-free survival of patients with different psychological stress levels.
- To evaluate the overall survival of patients with different psychological stress levels.
- To evaluate the quality of life of patients with different psychological stress levels.
Exploratory objectives:
-To evaluate the effect of managing the patient's psychological stress on the patient's immune microenvironment.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Xingyao Bu
- Phone Number: +86037165580295
- Email: xingyaobu@zzu.edu.cn
Study Contact Backup
- Name: Jie Mei
- Phone Number: +8615188318262
- Email: meijie@zzu.edu.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- age ≥18 years
- Karnofsky Performance Score ≥ 70 %
- histologically confirmed, previously untreated glioma receiving a standardized chemoradiotherapy regimen
- no previous history of mental illness, drug abuse, or alcohol abuse
- ability to communicate and read and write independently
- willing and able to comply with the protocol as judged by the investigator's signed informed consent.
Exclusion Criteria:
- Patients who have any other disease, either metabolic or psychological, or who have any evidence on clinical examination or special investigations (including laboratory findings) which give reasonable suspicion of a condition that interferes with the adequate measurement of the stress axis (e.g. chronic use of corticosteroids ≥ 3 months before study entry for diseases other than glioblastoma, (dexamethasone use in the context of glioblastoma is allowed) severe, medically treated psychiatric disorder prior to the diagnosis of glioblastoma Participation in a study with investigational drugs.
- pregnancy or breast-feeding
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurologic deficits that interfere with the planned walking tests, dementia, or confusional state.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observation group of newly oligodendroglioma patients with high-level psychological stress
The patients had high threshold levels of perceived psychological stress, fear, anxiety, and depression as assessed by psychologists
|
Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
|
Observation group of newly oligodendroglioma patients with low-level psychological stress
The patients had lower than threshold levels of perceived stress, psychological distress, fear, anxiety, and depression as assessed by psychologists
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of patients with high-level psychological stress
Time Frame: From the time of diagnosis to 8 years
|
The self-report questionnaire of Perceived Stress Scale (PSS) is used to measure the psychological stress level of patients, with 43 as the critical value, more than or equal to 43 as the high level of psychological stress, less than 43 as the low level of psychological stress.
|
From the time of diagnosis to 8 years
|
Tumor mutation burden (TMB)
Time Frame: From the time of diagnosis to 8 years
|
The proportion of tumor mutational burden ≥10 Mut/MB in the population who remain progression-free after diagnosis.
|
From the time of diagnosis to 8 years
|
The proportion of patients with tumor recurrence
Time Frame: From the time of diagnosis to 8 years
|
The proportion of patients with oligodendroglioma who had recurrence after tumor resection.
|
From the time of diagnosis to 8 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival at 5 years
Time Frame: From the time of diagnosis to 8 years
|
The proportion of participants in the analysis population who remain progression-free for at least 5 years after diagnosis.
|
From the time of diagnosis to 8 years
|
Overall survival rate at 8 years
Time Frame: From the time of diagnosis to 8 years
|
OS-36 is the proportion of participants in the analysis population who remain alive for at least 8 years after diagnosis.
|
From the time of diagnosis to 8 years
|
Progression-free survival at 8 years
Time Frame: From the time of diagnosis to 8 years
|
The proportion of participants in the analysis population who remain progression-free for at least 8 years after diagnosis.
|
From the time of diagnosis to 8 years
|
The Short Form-36 (SF-36)
Time Frame: From the time of diagnosis to 8 years
|
The questionnaire of Short Form-36 (SF-36) is used health-related quality- of-life measure in participants outcomes.
The scale contains 9 dimensions with a total score of 100 points.
|
From the time of diagnosis to 8 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Classification proportion of glioma recurrence
Time Frame: From the time of diagnosis to 8 years
|
Patients with recurrent gliomas undergo secondary surgery/needle biopsy to determine the type of recurrent glioma.
|
From the time of diagnosis to 8 years
|
Collaborators and Investigators
Investigators
- Study Director: Xingyao Bu, Henan Provincial People's Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Disease Progression
- Stress, Psychological
- Oligodendroglioma
Other Study ID Numbers
- HenanPPH-Oligodendroglioma
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oligodendroglioma, Adult
-
National Cancer Institute (NCI)TerminatedAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Ependymoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Myxopapillary Ependymoma | Adult Oligodendroglioma | Adult Pilocytic... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedAdult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Recurrent Adult Brain TumorUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Ependymoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Myxopapillary Ependymoma | Adult Oligodendroglioma | Adult Pilocytic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedAdult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Recurrent Adult Brain TumorUnited States
-
Northwestern UniversityTerminatedAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult GlioblastomaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Millennium Pharmaceuticals, Inc.CompletedAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Adult Pilocytic Astrocytoma | Adult Pineal Gland Astrocytoma | Recurrent... and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAnaplastic Oligoastrocytoma | Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnAdult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
National Cancer Institute (NCI)CompletedAdult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Recurrent Adult Brain NeoplasmUnited States
Clinical Trials on Stressors
-
Henan Provincial People's HospitalNot yet recruiting
-
Henan Provincial People's HospitalNot yet recruiting
-
The University of Texas at ArlingtonPenn State UniversityCompletedMajor Depressive DisorderUnited States
-
Indiana UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsRecruiting
-
University Hospital, ToulouseUnknown
-
VA Office of Research and DevelopmentRecruitingAnxiety | Depressive SymptomsUnited States
-
Ottawa Hospital Research InstituteUniversity of OttawaNot yet recruitingStress, Psychological | Stress, Physiological | Stress ReactionCanada
-
Oregon Health and Science UniversityRecruiting
-
Mezzion Pharma Co. LtdNational Heart, Lung, and Blood Institute (NHLBI)CompletedSingle Ventricle Heart DiseaseUnited States, Korea, Republic of, Canada